Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, "Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkin's Lymphoma of any of the Phase 3 Non-Hodgkin's Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007."

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkin's Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patient's own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... Texas , March 4, 2015 ... II pilot study in patients with moderate to ... Dermatology. The open-label Phase II trial evaluated the ... monoclonal antibody that targets interleukin-1 alpha (IL-1a). IL-1a ... inflammatory cells present in skin lesions. The Company ...
(Date:3/4/2015)... Pa. , March 4, 2015  Results of ... 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin ... poster session at the 32 nd Annual Miami ... study, conducted by Moshe Papa , MD, FACS, ... at Tel Aviv University, reports an analysis of MarginProbe,s ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
(Date:3/5/2015)... Obesity can cause the human body to ... drinks each day can help promote weight loss in ... advocate Sharon Kleyne and sports doctor Robert Weil, during ... of Water® radio show. , Weil is a ... and sports medicine. His weekly radio show, "The ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Hope For The ... Sporting Clay Shoot to be held at Beretta Shooting Grounds ... 2015. All proceeds from the event will benefit Hope For ... of self, restoring the family unit, and restoring hope for ... will honor our nation’s heroes through a day of clay ...
(Date:3/5/2015)... LOUISIANA (PRWEB) March 05, 2015 ... its continued support of the annual American Heart Association’s ... year, Bret Kolman, Lakeview Regional Chief Executive Officer, is ... place on Saturday, March 21, 2015 at Fontainebleau State ... sponsorship, Lakeview Regional has 20 individual teams participating in ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... Professor of Psychiatry and Psychology Department of Neuroscience, ... at the upcoming BioConference Live Neuroscience, a two-day ... , The webcast , titled “Dopamine System ... is scheduled for Thursday, March 18, from 9 ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... of the groundbreaking for Cielo Carmel on March 4 ... court will feature speakers: Sherri Lightner, Council president, ... Affirmed Housing; Charmaine Atherton, Senior Vice President, Southern ... Richard Gentry, President & CEO, San Diego Housing Commission. ...
Breaking Medicine News(10 mins):Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 2Health News:Obesity is dehydrating and drinking water promotes weight loss say fresh water advocates 3Health News:Hope For The Warriors Announces New York Clay Shoot to Benefit Military Families 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 2Health News:Get Your Heart Set on Walking a Better "Path" - Lakeview Regional Medical Center Sponsors Northshore Heart Walk 3Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 2Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 3Health News:SD City Council President Sherri Lightner and Affirmed Housing Break Ground on Affordable Homes in Carmel Valley 2
... CLARA, Calif., Dec. 3 Coherent, Inc.,(Nasdaq: COHR ... received the,decision of the Board of Directors of The ... 2007 to file its past due periodic reports,for the ... quarterly periods,of 2007 with the Securities Exchange Commission ("SEC") ...
... Mass., Dec. 3 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... the annual American Society of Hematology (ASH) meeting ... visiting the Investors section of the,Company,s website, ... The presentation will be delivered by Millennium ...
... first survey to specifically measure hospital pediatric preparedness, a ... researchers found few U.S. emergency rooms are properly equipped ... Charles Schmitz and Roger J. Lewis was reported in ... the American Academy of Pediatrics. The team of LA ...
... care and lack of transportation combine to limit access, CDC ... Almost 20 percent of Americans, or more than 40 million ... a new U.S. government report released Monday. , Access to ... United States, 2007 report from the Centers for Disease ...
... Vegas and Tucson Marathon Runners, PLEASANT GROVE, Utah, ... to prevent inflammation and pain, but at the same ... at,Appalachian State University and Vanderbilt University, published in,Medicine & ... exercise may be unhealthy in the long term. The ...
... Front Needs of Families with Deployed Service Members ... ... will present $15,000 to the Missouri National Guard -,Missouri Military Family Relief Fund, ... their families., Don Brown, market vice president for the central market area ...
Cached Medicine News:Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 2Health News:Coherent, Inc. Reports Decision by the Nasdaq Stock Market 3Health News:Millennium Pharmaceuticals Announces Webcast of American Society of Hematology Investor Event 2Health News:LA BioMed researchers find few emergency rooms fully equipped for pediatric patients 2Health News:Almost 1 in 5 Americans Going Without Health Care 2Health News:Almost 1 in 5 Americans Going Without Health Care 3Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2
... enables highly sensitive time-resolved fluorescence detection ... fluorophores. These compounds are excited with ... fluorescence lifetimes (several hundred microseconds), large ... profiles at 620 nm. Therefore with ...
... most advanced multi-functional microplate detection system, ... performance without compromising flexibility. ,The ... on the Ultra instrument platform. New ... adds to the flexibility of the ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... FLUOstar is a flexible multifunction plate reader ... one instrument: fluorescence intensity, time-resolved fluorescence, high-perfomance ... be equipped with injectors that deliver reagent ... fast kinetic cell assays can be performed ...
Medicine Products: